Top

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Published in:

Open Access 01-12-2021 | Diabetic Neuropathy | Research

High leukotriene B4 serum levels increase risk of painful diabetic neuropathy among type 2 diabetes mellitus patients

Authors: Kelvin Yuwanda, I Putu Eka Widyadharma, Dewa Putu Gde Purwa Samatra, I Made Oka Adnyana, Anna Marita Gelgel, I Komang Arimbawa

Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery | Issue 1/2021

Abstract

Background

Painful diabetic neuropathy is one of the most common complications of type 2 diabetes mellitus, with approximately 30–50% of people will experience diabetic neuropathy. Chronic hyperglycemia will cause an inflammatory process that will trigger an immune response included leukotrienes. Leukotriene B4 is associated with hemoglobin glycation levels. This study aimed to determine high serum leukotriene B4 levels and other factors as a risk factor for painful diabetic neuropathy in type 2 diabetes mellitus patient.

Results

Forty-two subjects with 22 cases (median age 56.5 ± 4.9 years) and 20 controls (median age 56.5 ± 5.2 years) group were collected. In bivariate analysis, significant factor for high risk PDN was high leukotriene B4 serum level (OR 5.10; 95% CI 1.34–19.4, p 0.014). Meanwhile, insignificant factors were anti-diabetic drugs (OR 2.139; 0.62–7.37; p = 0.226), and duration of diabetes mellitus (OR 2.282; 0.56–9.25; p = 0.315). Independent risk factor was serum leukotriene B4 levels (OR 5.10; 95% CI 1.336–19.470; p = 0.017).

Conclusions

In this study, high leukotriene B4 serum levels increase the risk of painful diabetic neuropathy among type 2 diabetes mellitus. The leukotriene B4 may consider as a potential biomarker for early detection in high risk for PDN and early treatment.

Kharroubi AT, Darwish HM. Diabetes mellitus: the epidemic of the century. World J Diabetes. 2015;6(6):850–67. https://doi.org/10.4239/wjd.v6.i6.850.CrossRefPubMedPubMedCentral

International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.

Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–93. https://doi.org/10.2337/dc10-1303.CrossRefPubMedPubMedCentral

Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, Abdalla K, et al. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. J Int Med Res. 2011;39(2):366–77. https://doi.org/10.1177/147323001103900204.CrossRefPubMed

Risson V, Nallagangula TK, Vasanthaprasad V. Incidence and prevalence of painful diabetic neuropathy and postherpetic neuralgia in major 5 European countries, the United States and Japan. Value Health. 2017;20(9):A547. https://doi.org/10.1016/j.val.2017.08.845.CrossRef

Reed C, Hong J, Novick D, Lenox-Smith A, Happich M. Incidence of diabetic peripheral neuropathic pain in primary care—a retrospective cohort study using the United Kingdom General Practice Research Database. Pragmat Obs Res. 2013;4:27–37. https://doi.org/10.2147/POR.S49746.CrossRefPubMedPubMedCentral

Aslam A, Singh J, Rajbhandari S. Prevalence of painful diabetic neuropathy using the Self-completed Leeds Assessment of Neuropathic Symptoms and Signs Questionnaire in a population with diabetes. Can J Diabetes. 2015;39(4):285–95. https://doi.org/10.1016/j.jcjd.2014.12.007.CrossRefPubMed

Salmen T, Pietrosel VA, Hernest G, Chiper GV, Florea DE, Popa LM, et al. Early diagnosis of peripheral diabetic neuropathy-something old that should always be considered something new. Rom J Diabetes Nutr Metab Dis. 2020;27(2):99–103. https://doi.org/10.46389/rjd-2020-1017.CrossRef

Omoigui S. The biochemical origin of pain-proposing a new law of pain: the origin of all pain is inflammation and the inflammatory response. Med Hypotheses. 2007;69(1):70–82. https://doi.org/10.1016/j.mehy.2006.11.028.CrossRefPubMedPubMedCentral

10.

Bhatt L, Roinestad K, Van T, Springman EB. Recent advances in clinical development of leukotriene B4 pathway drugs. Semin Immunol. 2017;33:65–73. https://doi.org/10.1016/j.smim.2017.08.007.CrossRefPubMed

11.

Herrada AA, Mejias C, Lazo-Amador R, Olane-Briones A, Lara D, Escobedo N. Development of new serum biomarkers for early lymphedema detection. Lymphat Res Biol. 2020;18(2):136–45. https://doi.org/10.1089/lrb.2019.0008.CrossRefPubMed

12.

Lantos LL, Wertaschnigg D, Rolnik DL, Costa FDS, Syngelaki A, Dimitriadis E, et al. Serum leukotriene B4 acid in the prediction of pre-eclampsia. Placenta. 2021;103:76–81. https://doi.org/10.1016/j.plasenta.2020.10.007.CrossRef

13.

Seggev JS, Thornton WH, Edes TE. Serum leukotriene B4 levels in patients with obstructive pulmonary diseases. Chest. 1991;99(2):289–91. https://doi.org/10.10378/chest.99.2.289.CrossRefPubMed

14.

Neves JAJ, Matos MRD, Ramalho T, Santos-Bezerra DP, Cavalcante CDGD, Peixoto RDA, et al. Increased leukotriene B4 plasma concentration in type 2 diabetes individuals with cardiovascular autonomic neuropathy. Diabetol Metab Syndr. 2020. https://doi.org/10.1186/s13098-020-00606-3.CrossRefPubMedPubMedCentral

15.

Spallone V, Greco C. Painful and painless diabetic neuropathy: one disease or two? Curr Diab Rep. 2013;13:533–49. https://doi.org/10.1007/s11892-013-0387-7.CrossRefPubMed

16.

Tahalli R, Zarini S, Sheibani N, Murphy RC, Gubitosi-Klug RA. Increased synthesis of leukotrienes in the mouse model of diabetic retinopathy. Invest Opthalmol Vis Sci. 2010;51(3):1699–708. https://doi.org/10.1167/iovs.09-3557.CrossRef

17.

Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: where are we now and where to go? J Diabetes Invest. 2010;2(1):18–32. https://doi.org/10.1111/j.2040-1124.2010.00070.x.CrossRef

18.

Allison DJ, Thomas A, Beaudry K, Ditor DS. Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial. J Neuroinflamm. 2016;13(1):152. https://doi.org/10.1186/s12974-016-0625-4.CrossRef

19.

Noguchi K, Okubo M. Leukotrienes in nociceptive pathway and neuropathic/inflammatory pain. Biol Pharm Bull. 2011;34(8):1163–9. https://doi.org/10.1248/bpb.34.1163.CrossRefPubMed

20.

Kiyoyuki Y, Taniguchi W, Okubo M, Yamanaka H, Kobayashi K, Nishio N, et al. Leukotriene enhances NMDA-induced inward currents in dorsal horn neurons of the rat spinal cord after peripheral nerve injury. Mol Pain. 2015;11:53. https://doi.org/10.1186/s12990-015-0059-5.CrossRefPubMedPubMedCentral

21.

Suryavanshi SV, Kulkarni YA. NF-kB: a potential target in the management of vascular complications of diabetes. Front Pharmacol. 2017;8:798. https://doi.org/10.3389/fphar.2017.00798.CrossRefPubMedPubMedCentral

Title: High leukotriene B4 serum levels increase risk of painful diabetic neuropathy among type 2 diabetes mellitus patients
Authors: Kelvin Yuwanda
I Putu Eka Widyadharma
Dewa Putu Gde Purwa Samatra
I Made Oka Adnyana
Anna Marita Gelgel
I Komang Arimbawa
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Diabetic Neuropathy
Diabetic Neuropathy
Diabetes
Type 2 Diabetes
Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery / Issue 1/2021
Electronic ISSN: 1687-8329
DOI: https://doi.org/10.1186/s41983-021-00375-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

High leukotriene B4 serum levels increase risk of painful diabetic neuropathy among type 2 diabetes mellitus patients

Abstract

Background

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Case report on Cotard’s syndrome (CS) in a patient with schizophrenia: a rare case from Malaysia

Epidemiological profile of brain tumors in Cameroon: a retrospective study

Helicobacter pylori antibodies and multiple sclerosis: a single-center study and a short review of the literature

Depression and COVID-19 patients with chronic pain: practical considerations

Outcomes and issues of 12 chordomas treated in a single center

Sequential approach of internal maxillary-to-middle cerebral artery bypass and endovascular occlusion for giant middle cerebral artery aneurysm: a case report